Abcam plc

• Abcam plc
• Health-Care

ABCM

We are a global life science company focused on identifying, developing and distributing high-quality reagents and tools for our customers at the forefront of life science research. Our products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery. Our mission is to provide life science researchers with highly validated products and services to advance biological research and achieve their goals faster. We do this by continuously innovating and providing our customers with high-quality tools, together with expert customer support. Our product offering includes an extensive portfolio of antibodies and related protein research tools that are fundamental to our customers’ research and experimental workflow. Our customers are primarily scientists and researchers in academic institutions, research institutes and pharmaceutical, biotechnology and diagnostics companies. Headquartered in Cambridge, United Kingdom, we operate across 15 locations around the world, supported by our world-class team of approximately 1,500 employees, including over 200 PhDs, and have served customers in over 130 countries.

Our addressable market can be broadly classified into two categories, based on the application of our products and type of customer they serve:

       • Research use only proteomic tools. We believe the global market for RUO antibodies and reagents is valued at approximately $3 billion as of 2019 and, as of 2019, was expected to grow at around 4% per annum (excluding any impact from COVID). These products include protein binding reagents, such as primary and secondary antibodies and singleplex and multiplex immunoassays, and related reagents, such as kits, proteins, peptides, lysates, cell lines and biochemicals. Our research products are used to detect, quantify, visualize and modify proteins in scientific research experiments, which we believe serve as mission critical tools, to enable our customers to develop insights about targets and pathways of interest. Our customers include academic labs for scientific research and clinical labs in pharmaceutical and biotechnology companies working in the drug discovery and diagnostic markets. Our catalogue revenue, the substantial majority of which is purchased for RUO, accounted for 93.5% of our total revenue for the fiscal year ended June 30, 2020.

      • Antibody development for clinical application. Antibodies are a critical component in many IVD assays and can also be used as therapeutic agents for the treatment of diseases, including cancers and immune-related diseases. In recent years, through the custom development of new antibodies and the out-licensing of our existing antibodies to biopharmaceutical and diagnostic companies, we have extended the commercial potential of our products into these markets. The substantial majority of our Custom Products and Licensing revenue, which includes custom development services, IVD sales and royalty and license income, is generated from these activities, and accounted for 6.5% of our total revenue for the fiscal year ended June 30, 2020.

Life science researchers are increasingly seeking higher quality tools and reagents, which deliver consistent, reproducible results, save time, uncover deeper biological insights and advance their research. We believe customers place their trust in Abcam because of our reputation for providing reliable, highly validated products with market leading specificity and high sensitivity, comprehensive and transparent product data, fast delivery and exceptional customer support. According to CiteAb, our products were cited in approximately half of all life science publications in 2019, and we were the most cited company in approximately 40% of the top 2,000 most studied protein targets as of June 30, 2020. 

Offering Team

Pre-IPO Investors

Deal Highlights

less

More

Deal Tracker

Stock Price